近日，昆山益腾医疗科技有限公司（以下简称"益腾科技"）宣布完成近亿元A轮融资。本轮融资由 弘晖基 金领投，昆山国创集团、昆玉人才基金跟投，启峰资本担任本轮财务顾问 ，所募资金将重点用于高端CT 球管的研发迭代与注册推进，为公司持续领跑国产CT球管赛道注入强劲资本动力。作为国内电真空技术领 域的高新技术企业，益腾科技凭借创始人顶尖行业积淀、产品卓越性能及快速商业化落地能力，在高端医 疗装备核心部件国产化浪潮中脱颖而出，成功破解CT球管"卡脖子"难题。 01 复合背景创始人引领技术突围，30年行业积淀贯通产学研 益腾科技创始人邹昀博士曾于清华大学、马里兰大学深造加速器和真空电子束流技术，后加入国际头部企 业主导先进CT球管的研发与产品线搭建，深刻洞察CT球管的核心技术难点与产业化痛点。 通知 | 关于举办"2026大湾区工业具身智能大会"的通知 背靠创始人"顶尖学府学术底蕴+国际大厂产业经验"兼具的行业稀缺优势，再加持公司在电真空，材料， 工艺等各关键环节强大的人才储备，益腾科技实现了从基础研究到工程量产的无缝贯通，打破了国内多数 企业"研发与量产脱节"的困境。 公司成立仅2年内便实现首款5.5MHU球管的研发落 ...

Group 1 - The State Administration for Market Regulation has released 32 national metrology technical standards covering various fields including intelligent connected vehicles, health, and smart meters [1][2] - In the field of intelligent connected vehicles, the "Measurement Testing Specification for Automatic Parking Performance of Intelligent Connected Vehicles" is the first professional standard in China, filling a technical gap and promoting the unified and comparable results of automatic parking parameter testing [1] - In the health sector, the "Calibration Procedure for Electrocardiogram Machines" standardizes the metrology performance requirements for both analog and digital ECG machines, ensuring accurate diagnostic data for patient health [1] Group 2 - In the field of electric energy metering, the "Calibration Procedure for Installed AC Energy Meters" consolidates five previous standards, enhancing technical requirements and operational feasibility, while addressing public concerns regarding measurement errors [2] - The new standards include guidelines for determining calibration cycles for measuring instruments and performance evaluation for instruments with additional functions, laying the foundation for upgrading metrology technical standards [2]

Core Viewpoint - Mindray Medical's stock price has shown fluctuations, with a recent increase of 2.10% to 192.11 CNY per share, while the company faces a decline in revenue and profit year-on-year [1][2]. Group 1: Stock Performance - As of February 4, Mindray Medical's stock price increased by 2.10%, reaching 192.11 CNY per share, with a trading volume of 1.136 billion CNY and a turnover rate of 0.50% [1]. - Year-to-date, the stock price has risen by 0.87%, with a 5-day increase of 2.15%, but a decline of 4.36% over the past 20 days and 7.64% over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Mindray Medical reported a revenue of 25.834 billion CNY, a year-on-year decrease of 12.38%, and a net profit attributable to shareholders of 7.570 billion CNY, down 28.83% year-on-year [2]. - Since its A-share listing, Mindray Medical has distributed a total of 35.336 billion CNY in dividends, with 25.025 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Mindray Medical reached 108,800, an increase of 18.86% from the previous period, while the average number of circulating shares per person decreased by 15.87% to 11,139 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 117 million shares, a decrease of 14.736 million shares from the previous period [3].

序号股东名称持股比例1北京华睿博视医学影像技术有限公司100% 经营范围含第二类医疗器械销售；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广； 专用设备修理；第一类医疗器械销售；第二类医疗设备租赁；医学研究和试验发展；第一类医疗设备租 赁；仪器仪表销售；信息技术咨询服务；科技中介服务；科技推广和应用服务；技术推广服务；软件销 售；软件开发；电子专用材料销售；电子专用材料研发；信息系统集成服务；专业设计服务；图文设计 制作；工业设计服务；集成电路设计；集成电路芯片设计及服务；机械设备研发；电子产品销售；专用 化学产品销售（不含危险化学品）；货物进出口；技术进出口（除依法须经批准的项目外，凭营业执照 依法自主开展经营活动） 天眼查显示，近日，江苏华睿博通医疗设备有限公司成立，法定代表人为张昕，注册资本5000万人民 币，由北京华睿博视医学影像技术有限公司全资持股。 企业名称江苏华睿博通医疗设备有限公司法定代表人张昕注册资本5000万人民币国标行业科学研究和技 术服务业>科技推广和应用服务业>技术推广服务地址中国（江苏）自由贸易试验区苏州片区苏州工业 园区现代大道88号物流大厦（112）室企业类型有限责 ...

Key Points - The stock price of Ruimaite (301367) closed at 82.71 yuan on February 3, 2026, with an increase of 1.86% and a turnover rate of 1.07% [1] - The trading volume was 7,472 lots, with a total transaction amount of 61.1885 million yuan [1] Trading Information Summary - On February 3, 2026, the net outflow of main funds was 948,300 yuan, while the net inflow of retail funds was 3,289,100 yuan [1][3] Company Announcement Summary - Ruimaite held its 18th meeting of the third board of directors on February 3, 2026, where it approved adjustments to the internal investment structure of certain fundraising projects and the postponement of some projects [1] - The board's decision was unanimous, with all 9 directors voting in favor, and the adjustments are aimed at improving the efficiency of fund usage and optimizing resource allocation [1] - The company will reduce investment in channel construction and overseas branches for the "Marketing Network and Brand Building Project" while increasing marketing promotion investment [2] - For the "Medical Equipment R&D Center Project," the company will increase R&D investment and reduce expenditures on decoration and equipment [2] - The expected completion dates for the "Annual Production of 300,000 Ventilators and 3.5 Million Sets of Accessories" and "Marketing Network and Brand Building Project" have been postponed to December 31, 2027, while the "Medical Equipment R&D Center Project" is postponed to December 31, 2026 [1][2]

Core Viewpoint - The report indicates that 港通医疗 (Sichuan Porton Medical Equipment Group Co., Ltd.) is facing a projected loss for the year 2025, marking a significant shift from profit to loss, alongside delays in some fundraising projects due to external factors [1] Group 1: Stock Performance - As of February 3, 2026, 港通医疗's stock closed at 25.21 yuan, reflecting a 4.0% increase from the previous trading day [1] - The stock opened at 24.76 yuan, reached a high of 25.47 yuan, and a low of 24.22 yuan, with a trading volume of 73.46 million yuan and a turnover rate of 4.51% [1] Group 2: Regulatory Compliance - The report from 中信建投证券 (CITIC Securities) regarding the 2025 annual continuous supervision inspection indicates that the company is generally compliant in areas such as corporate governance, internal control, information disclosure, and use of raised funds [1] - However, the company is expected to incur a loss between 2 million to 4 million yuan for the year 2025, which is a reversal from previous profits [1] - Some fundraising projects are experiencing slower construction progress than anticipated, leading to the execution of delay procedures and subsequent announcements [1]

Core Viewpoint - The company, Sichuan Portong Medical Equipment Group Co., Ltd., specializes in medical gas equipment and cleanroom systems, with a focus on the development, design, manufacturing, integration, and operation services of these systems [3]. Business Overview - The main business of the company includes medical gas equipment and systems (55.69% of revenue), cleanroom equipment and systems (37.30%), sales of medical devices and other products (4.06%), operation services (2.81%), and other supplementary services (0.14%) [8]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3]. Recent Developments - The company has developed the Portong Cloud Monitoring Platform, which utilizes advanced IoT technology to provide real-time monitoring solutions for medical equipment in hospitals [2]. - As of January 30, the number of shareholders in Portong Medical was 9,164, a decrease of 4.48% from the previous period, while the average number of circulating shares per person increased by 4.69% [8]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to the parent company of -10.21 million yuan, a year-on-year decrease of 150.92% [8]. - The company has distributed a total of 48.9973 million yuan in dividends since its A-share listing [9]. Market Activity - On February 3, the stock price of Portong Medical increased by 4.00%, with a trading volume of 73.4646 million yuan and a turnover rate of 4.51%, bringing the total market capitalization to 2.521 billion yuan [1]. - The stock has experienced a net outflow of 1.1368 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5].

Core Viewpoint - The new regulations aim to address the issue of "abnormally low bids" in government procurement, particularly in the medical equipment sector, by establishing a more transparent and competitive market order focused on quality and price [1][8]. Group 1: Key Issues in Abnormally Low Bids - The core reasons for the persistence of abnormally low bids include a business model driven by profit bundling, procurement and evaluation mechanism loopholes, and weak regulatory and performance systems [2]. - The binding of equipment and consumables leads to a cycle where companies use low initial bids to capture hospital channels, later profiting from consumables and maintenance services [2]. - The evaluation process often prioritizes price over total lifecycle costs, neglecting long-term expenses related to consumables and maintenance, which creates opportunities for low-price collusion [2]. Group 2: Key Measures to Avoid Quality Decline - A comprehensive prevention system must be established across five key areas: source demand control, evaluation optimization, contract and performance constraints, acceptance supervision, and intelligent empowerment [3][4][5]. - Source demand control should involve thorough market research to accurately determine lifecycle costs, ensuring procurement budgets reflect actual needs [3]. - The evaluation mechanism should prioritize technical and service quality over price, requiring suppliers to justify low bids with detailed cost breakdowns [3]. Group 3: Impact of New Regulations on the Industry - The new regulations will significantly impact procurement entities (hospitals), suppliers, and regulatory bodies, accelerating industry reshuffling and concentrating market share among quality enterprises [6][7]. - Hospitals will benefit from reduced lifecycle costs and increased focus on comprehensive value assessments, but will need to invest more in market research and adjust internal evaluation criteria [6]. - Leading companies with core technology and compliance capabilities will thrive, while smaller firms may struggle to adapt, leading to a market shift towards quality competition and breaking traditional profit models [6][7]. Group 4: Regulatory Enhancements - The new regulations provide clear guidelines for managing abnormally low bids, enhancing transparency and efficiency in government procurement [7]. - Regulatory bodies will need to establish collaborative oversight mechanisms to ensure accountability across all parties involved in the procurement process [7]. - The market will increasingly favor companies with robust compliance and service capabilities, as the separation of equipment and consumables procurement disrupts previous profit bundling practices [7][8].

本文字数：2121，阅读时长大约4分钟 2026.02. 03 作者 | 第一财经 秦新安 这是本月国家医保局曝光的第四起典型回扣案。在此之前，国家医保局已先后曝光黑龙江省双丰林业局职工医院内科医生党某海犯非国家工作人员受贿 罪案、重庆康荣医疗设备有限公司实际控制人王某向重庆某医院院长孙某行贿案，以及山东某医用高分子制品公司业务员慈某龙向普洱市人民医院工作 人员行贿案。几起案件暴露了医药商业贿赂的猖獗，也展示了医保部门打击医药商业贿赂、维护医保基金安全的决心。 国家医保局指出，医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药负担，使得医药产品销售从实 际临床价值和产品竞争力的竞争，转为以高返点和高回扣驱动的不当竞争。陕西李某受贿案就呈现医药商业贿赂的典型特征。一方面，受贿方利用科室 主任对科室使用耗材的决策权，在众多可选产品中优先选用给予高额回扣的贴牌耗材；另一方面，行贿方将事先约定回扣计入供货成本，最终通过医保 基金与患者自付"埋单"。 医药商业贿赂屡禁不止，背后是复杂的利益链条与制度漏洞。长期以来，在部分医疗领域，特别是高值耗材与药品销售中，"带金销售"成为一些企 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 原标题：300310宣布：10年前豪掷10亿元收购的子公司破产，财产已完成分配，公司仅分得83万元！此 前称收购时遭遇合同诈骗，已起诉 宜通世纪（维权）（SZ300310）斥资10亿元跨界并购过来的标的，如今走到了破产终结的结局，而宜 通世纪仅获得83万元的破产财产分配。 2月2日晚间，宜通世纪发布公告称，其曾经的全资子公司深圳市倍泰健康测量分析技术有限公司（以下 简称"倍泰健康"）破产程序终结。 这起曾被寄予厚望、旨在跨界智慧医疗的收购，最终演变为一场"噩梦"。从2018年倍泰健康"爆雷"开 始，宜通世纪不仅要因其业绩崩盘计提巨额商誉减值，还惹了一身的麻烦。 公司仅获83万元分配款 宜通世纪最新公告显示，公司近日收到广东省深圳市中级人民法院出具的《民事裁定书》，其债务人倍 泰健康被法院裁定终结破产程序。 公告显示，倍泰健康的破产清算申请于2023年11月13日被法院受理，倍泰健康于2026年1月26日被法院 裁定宣告破产。 据倍泰健康的《破产财产分配方案》，宜通世纪作为债权人，可获得分配的破产财产金额约83万元。宜 通世纪在公告中表示 ...